Appeal No. 1998-0350
Application No. 08/453,937
4. A method of inhibiting blood coagulation in whole blood plasma of a
warm blooded mammal comprising exogenously administering to said mammal
an effective synergistic anticoagulant amount of an anticoagulant sulfated
polysaccharide and LACI essentially free from antithrombin.
The examiner relies on the following references:
Broze, Jr. et al. (Broze), “The Lipoprotein-Associated Coagulation Inhibitor That
Inhibits the Factor VII-Tissue Factor Complex Also Inhibits Factor Xa: Insight
Into Its Possible Mechanism of Action,” Blood, Vol. 71, No. 2, pages 335-343
(1988).
Sandset et al. (Sandset),”Heparin Induces Release of Extrinsic Coagulation
Pathway Inhibitor (EPI),” Thrombosis Research, Vol. 50, No. 6, pages 803-813
(1988).
Rapaport, “Inhibition of Factor VIIa/Tissue Factor-Induced Blood Coagulation:
With Particular Emphasis Upon a Factor Xa-Dependent Inhibitory Mechanism,”
Blood, Vol. 73, No. 2, pages 359-365 (1989).
Girard et al. (Girard), “Inhibition of Factor VIIa -Tissue Factor Coagulation Activity
by a Hybrid Protein,” Science, Vol. 248, pages 1421-1424 (1990).
Claims 1 and 2 stand rejected under 35 U.S.C. § 102(b) as anticipated by
Broze.
Claims 4 and 5 stand rejected under 35 U.S.C. § 103 as obvious over
Broze and Sandset.
Claims 3 and 6 stand rejected under 35 U.S.C. § 103 as obvious over
Broze, Sandset, Rapaport, and Girard.
We reverse.
Background
Blood clotting can be activated via the intrinsic or the extrinsic coagulation
pathway. Specification, page 1. Lipoprotein-associated coagulation inhibitor
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: November 3, 2007